Vaccines
Also known as: Immunization, Vaccination
Methodology & AI Transparency ⓘ
Vaccines Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What are vaccines? Vaccines are injections (shots), liquids, pills, or nasal sprays that you take to teach your body's immune system to recognize and defend against harmful germs.
- 2 Real-world patient consensus: Diagnostic registry B00.8: Vaccines is managed within Infections & Antivirals (aka Immunization).
- 3 Typical cash cost range: Differential triage of Vaccines (B00.8) utilizes antimicrobial stewardship (narrow-spectrum in Vaccines (B00.8: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Follow-up benchmark in Vaccines: maintaining Targeted PCR / in Vaccines (B00.8: Culture & Sensitivity) within Pathogen clearance / negative test (B00.8).
Ask our AI Specialists anything about Vaccines
What Is Vaccines?
What are vaccines? Vaccines are injections (shots), liquids, pills, or nasal sprays that you take to teach your body's immune system to recognize and defend against harmful germs. For example, there are vaccines to protect against diseases caused by: Viruses , like the ones that cause the flu and COVID-19 Bacteria , including tetanus, diphtheria, and pertussis What are the types of vaccines? There are several types of vaccines: Live-attenuated vaccines use a weakened form of the germ. Inactivated vaccines use a killed version of the germ.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Vaccines (B00.8) features localized inflammatory exudate [Vaccines B00.8]. Cross-referenced with NIH MeSH (Vaccination, Immunization), therapeutic stabilization in infections & antivirals is verified against Complete Blood Count in Vaccines (B00.8: (WBC & Differential)).
Common Symptoms & Clinical Signs
- • Viruses , like the ones that cause the flu and COVID-19
- • Bacteria , including tetanus, diphtheria, and pertussis
- • Presentation of Vaccines (B00.8): sore throat, productive in Vaccines (B00.8: cough, sinus/ear pain,)
- • Secondary Vaccines clinical sign: painful vesicular rash in Vaccines (B00.8: in a dermatomal)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Vaccines Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B00.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Targeted PCR / in Vaccines (B00.8: Culture & Sensitivity) | Pathogen clearance / negative test (B00.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Vaccines (B00.8: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B00.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Vaccines (B00.8: Procalcitonin) | Resolution to baseline (B00.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Vaccines
Treatment selection for Vaccines depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vaccines)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on A phase 3, randomized, gold-standard blind study to evaluate the immunogenicity: What a 1,710-Participant Study Found Three different lots of PCV20 demonstrated robust and consistent immunogenicity. Vaccine • 2021-09-07 • Phase III Randomized Trial | N = 1,710 | 96/100 | PMID 34315611 ↗ |
| New Insights on An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an: What a 1,030-Participant Study Found Safety and immunogenicity data of MVC-COV1901 from the study in Paraguay confirm previous results. Vaccine • 2023-01-04 • Phase III Randomized Trial | N = 1,030 | 96/100 | PMID 36404171 ↗ |
| New Insights on Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children: What a 3,765-Participant Study Found The variability in VE algorithms indicates challenges in accurately assessing VE against asymptomatic infections. The Journal of infectious diseases • 2025-07-11 • Phase III Randomized Trial | N = 3,765 | 96/100 | PMID 40100744 ↗ |
| New Insights on Immunogenicity and safety of live attenuated influenza vaccine in children aged: What a 3,000-Participant Study Found (3) Results: Although there was no significant difference in frequencies of all solicited or unsolicited AEs, nasal congestion, headache, and muscle pain were statistically significantly more frequent in vaccine recipients as... Vaccine • 2025-02-06 • Phase III Randomized Trial | N = 3,000 | 96/100 | PMID 39729925 ↗ |
| Can You Get Your RSV and Flu Shots at the Same Visit? What a 1,900-Adult Trial Found Coadminstration is estimated to maintain the efficacy of mRNA-1345 against RSV-lower breathing tract disease based on a correlate of protection model. Human vaccines & immunotherapeutics • 2026-12-15 • Phase III Randomized Trial | N = 1,900 | 96/100 | PMID 42048601 ↗ |
Vaccines Patient Community & “People Like Me” Threads
Filter Vaccines community threads and patient logs by age, biological sex, dosage, and treatment duration.